MTOR and myeloid sarcoma: Current evidence suggests that metformin’s activation of AMPK and modulation of the mTOR pathway may provide beneficial effects in MS through multiple mechanisms, including immunomodulation, neuroprotection, and metabolic regulation [277,278,279,280].